Share via Email


* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is 54.144.100.123)
* Email Subject: (personalize your message)


Email Content:

Zoetis Reports on Q3 of FY 2018

11/01/2018

In a press release dated November 1st 2018 Zoetis (ZTS) announced results for the 3rd Quarter of Fiscal 2018 ending September 30th 2018.

The following table summarizes the results for the period compared with the values for the corresponding quarter of the previous fiscal year (Values expressed as $ x 1,000 except EPS)

Quarter Ending. Sept. 30th

2018

2017

Difference (%)

Sales:

$1,480,000

$1,347,000

+9.8

Gross profit:

$1,007,000

$912,000

+10.4

Operating income:

$561,000

$457,000

+22.8

Net Income

$347,000

$296,000

+17.2

Diluted earnings per share:

$0.71

$0.61

+16.4

Gross Margin (%)

68.0

67.7

+0.4

Operating Margin (%)

37.9

33.9

+11.8

Profit Margin (%)

23.5

22.0

+6.8

Long-term Debt: Dec 31st. 2017/2016

$4,953,000

$4,468,000

+10.9

12 Months Trailing:

     

Return on Assets (%)

12.1

   

Return on Equity (%)

83.5

   

Operating Margin (%)

32.7

   

Profit Margin (%)

16.3

   

Total Assets Dec 31st. 2017/2016

$8,506,000

$4,468,000

+10.9

Market Capitalization

$45,000,000

   

52-Week Range in Share Price: $67.44 to $96.57

Market Close Nov. 1st $94.25 (+4.6%)

Forward P/E: 32.6

Livestock sales represented 52.6 percent of revenue (55.9 percent Q3 2017); Poultry represented 8.8 percent of sales (8.8 percent) International sales were 47.9 percent of revenue (33.9 percent)

Juan Ramón Alaix, CEO of Zoetis commented "continued delivering strong results in the third quarter, with 12% operational growth in revenue and 32% operational growth in adjusted net income," He added "our companion animal products performed well, primarily based on our key dermatology brands, new parasiticides and the addition of the Abaxis diagnostics portfolio. Meanwhile, in livestock products, our swine, poultry and fish portfolios each delivered double-digit growth, with more modest growth in our cattle business. Our diverse portfolio provided us with steady performance across markets, species and therapeutic areas, and we continue to invest internally and externally to support future growth."

F0r FY 2018 ZTS provided guidance for revenue of $5.75 billion to $5.85 billion, with EPS ranging from $3.08 to $3.13.